Page 3 - Nppa

NPPA asks hospitals, stent makers to list prices on websites

NPPA also asked stent makers, marketers and importers to undertake similar exercise

Drug price regulator identifies 3 hospitals overcharging for stents

As the controversy on stent availability and pricing intensifies, the National Pharmaceutical Pricing Authority (NPPA) has now started to crack the whip on hospitals. The pharma pricing authority said that three hospitals have been identified to be overcharging based on complaints it received on its helpline. The NPPA is investigating these matters. Last week the pharma pricing authority ordered cap on prices for stents, which are used for treating narrow or weak arteries, last week. In a notification, it set the cap of Rs 7260 for bare metal stents and Rs 29,600 for drug eluting as well as well as biodegradable stents. As the NPPA has no jurisdiction to curb the price of ancillary products such as balloon-catheters and guide wires, its strategy is to ensure that that manufacturers and hospitals do not try to create an artificial shortage. The NPPA also cannot control procedure costs at hospitals."Hospitals must first raise demand to company before complaining of shortage," says ...

Expert panel recommends expanding NPPA's mandate

At present, the NPPA monitors drugs that are part of NLEM and identifies players that overcharge

Regulator should fix prices for drugs not in essential list too: Panel

At present, the NPPA monitors drugs which are part of the National List of Essential Medicines

Pharma price regulator asks manufacturers to submit stent pricing data within one week

The notification was issued on 5th October, 2016

NPPA approves norms for discontinuation of scheduled drugs

The body may also consider an upwards price revision if the drug is being discontinued because of non remunerative pricing

Grim diagnosis for pharma firms haunted by price bogey

DoP directs NPPA to dig up 37-year-old cases of overpriced drugs

NPPA to cap coronary stent prices

Will meet industry representatives this month for inputs on stent prices

NPPA caps prices of another 50 drugs

The agency is also planning to cap the prices of 40 other drugs.

NPPA examining 92 applications to fix price of new FDCs

Also, last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend

NPPA caps prices of 70 new drugs

This is part of the new drug pricing control order notified on March 14, which effectively brings 200 more drug formulations under regulation